MegaPro Biomedical Co., Ltd. (“MegaPro Biomedical”, TPEx: 6827) today announced that its proprietary, nanotechnology‑enabled cell therapy product MPB‑2354 has been selected as a Top 8 finalist in the Healthcare sector at the 2026 SelectUSA Tech Startup Competition, part of the SelectUSA Investment Summit organized by the U.S. Department of Commerce.
MegaPro Biomedical is scheduled to join the delegation led by Taiwan’s Ministry of Economic Affairs to the United States in early May, where the company will participate in related SelectUSA activities and engage with startup ecosystems and international investors in Los Angeles, San Francisco, and Silicon Valley. This recognition reflects the strong evaluation of MegaPro Biomedical’s nanotechnology platform in terms of innovation, clinical development potential, and global market positioning by U.S. government and professional review panels.
MPB‑2354 is an allogeneic adipose‑derived stem cell therapy developed based on MegaPro Biomedical’s proprietary nanoparticle technology platform, and is uniquely combined with MRI contrast imaging technology. The product demonstrates dual functionality, offering both anti‑inflammatory therapeutic effects and real‑time in vivo imaging capability, representing a meaningful advancement in addressing key challenges in cell therapy. Through MRI‑based tracking, clinicians can monitor cell localization, retention, and status after administration, thereby enhancing quality control and safety assessment in cell‑based treatments.
In addition, MPB‑2354 is compatible with a wide range of cell therapy products, including mesenchymal stem cells (MSCs), T cells, and dendritic cells (DCs), without altering the intrinsic characteristics of the cells. This compatibility enables potential future integration with various existing and emerging cell therapy modalities.
MegaPro Biomedical noted that MPB‑2354 is currently advancing through preclinical development in accordance with its established R&D and regulatory roadmap. Selection into SelectUSA is expected to further strengthen the company’s understanding of the U.S. biomedical ecosystem and clinical resources, and will serve as an important reference for evaluating future U.S. clinical trials, strategic partnerships, and market entry strategies. The company will prudently assess opportunities related to U.S. presence establishment, regulatory advancement, clinical development, and strategic collaborations as part of its international expansion strategy.
MegaPro Biomedical will continue to focus on the development of its nanoparticle technology platform, aiming to build a globally differentiated cell‑visualization technology platform. The company has established a diversified pipeline including MPB‑1523 MRI contrast agent for hepatocellular carcinoma, MPB‑2043 MRI contrast agent for lymph node imaging, and MPB‑2354 cell therapy product. Going forward, MegaPro Biomedical plans to further integrate nanoparticle technology with cell therapies, actively pursue international market opportunities and strategic partnerships, and continue to build long‑term R&D value and sustainable growth momentum.
About MegaPro Biomedical
MegaPro Biomedical (TPEx: 6827) was established in 2014 as a spin‑off from the Industrial Technology Research Institute (ITRI). The company is a specialty pharmaceutical developer focused on niche nanomedicine technologies. MegaPro Biomedical operates two proprietary nanotechnology platforms—nanoparticles and nanomicelles—and has developed nanometer‑scale iron oxide products.
The company’s product portfolio includes MPB‑1514 (injectable iron supplement for iron deficiency anemia), MPB‑1523 (MRI contrast agent for hepatocellular carcinoma), MPB‑2043 (MRI contrast agent for lymph node staging), MPB‑2354 (cell therapy product), and MPB‑1734 (novel anticancer drug formulation).
For more information, please visit:
Forward‑Looking Statements
This press release contains forward‑looking statements that involve risks and uncertainties. Except for statements of historical fact, all statements regarding MegaPro Biomedical’s future operations, business outlook, plans, and prospects are forward‑looking statements. Actual results may differ materially due to various factors, including but not limited to price fluctuations, actual demand, exchange rate movements, market competition, regulatory and legal changes, global economic and financial conditions, political risks, cost estimates, and other risks beyond the company’s control. These forward‑looking statements are based on current expectations, and the company undertakes no obligation to update them in the future.